Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Accumulated Expenses (2023 - 2026)

Prelude Therapeutics' Other Accumulated Expenses history spans 4 years, with the latest figure at $911000.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 30.89% to $911000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $911000.0, a 30.89% increase, with the full-year FY2025 number at $965000.0, up 25.16% from a year prior.
  • Other Accumulated Expenses hit $911000.0 in Q1 2026 for Prelude Therapeutics, down from $965000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for PRLD hit a ceiling of $965000.0 in Q4 2025 and a floor of $455000.0 in Q2 2024.
  • Historically, Other Accumulated Expenses has averaged $816800.0 across 4 years, with a median of $831000.0 in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: decreased 18.41% in 2024 and later skyrocketed 89.23% in 2025.
  • Tracing PRLD's Other Accumulated Expenses over 4 years: stood at $945000.0 in 2023, then decreased by 18.41% to $771000.0 in 2024, then rose by 25.16% to $965000.0 in 2025, then decreased by 5.6% to $911000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for PRLD at $911000.0 in Q1 2026, $965000.0 in Q4 2025, and $963000.0 in Q3 2025.